Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial

Authors : Michael Walsh, David Collister, Martin Gallagher, Patrick B Mark, Janak R de Zoysa, Jessica Tyrwhitt, Karthik Tennankore, Gilmar Reis, *Denis Xavier*, Wen J Liu, Li Zuo, Amanda Y Wang, Camilo Félix, *Atiya R Faruqui*, Mavel López-Flecher, Lonnie Pyne, Ron Wald, Fei Yuan, Kumar Balasubramanian, Shun Fu Lee, Alena Kuptsova, Courtney Christou, PJ Devereaux, Akshaya R Faruqui, *Freeda Xavier*, *Preeti Girish*, Remya Giriraju, Susan Subbin, Jagannath Rao, et al…

Publication Year : 2025

Abstract :

Background: 

Patients undergoing maintenance dialysis for kidney failure are at substantial risk of cardiovascular morbidity and mortality. We aimed to establish if spironolactone reduces heart failure and cardiovascular deaths in these patients.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01198-5/abstract